RxDoctor Payments Data

Angelique Sawyer

Optometrist · North Conway, NHNPI 1114174950

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,500 of the $2,083 with a category attached, or 72.0%. Bausch & Lomb, A Division Of Bausch Health US, LLC accounts for 72.0% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $1,542 and has fallen 92.5% since, to $115 in 2025.

$2,083in general payments, 2019–2025

Across 18 payments — averaging $115.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
  • Bausch & Lomb Americas Inc.$220
  • AbbVie$106
  • Glaukos Corporation$74
  • Alcon$63
  • Coopervision Inc.$54
  • plus $66 from 4 others

What the payments were for

  • Speaking & faculty fees$1,50072%
  • Food & beverage$58328%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,083 in reported general payments places this provider in the 80th percentile of 235 optometrist providers in New Hampshire.

See all optometrist providers in New Hampshire

Medicare billing

Part B allowed, 2024
$133,280
Medicare patients
717
Services billed
1,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost61$44,453
RestasisCyclosporine28$41,559
SimbrinzaBrinzolamide/Brimonidine Tart19$5,338
CombiganBrimonidine Tartrate/Timolol13$4,453
Latanoprost200$1,998
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat85$1,901
Betaxolol Hcl19$1,842
Fluorometholone23$1,580
Timolol Maleate130$1,154
Brimonidine Tartrate48$606
Prednisolone Acetate12$487
Dorzolamide Hcl21$245
Doxycycline Monohydrate13$190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$106$90,465102 claims
AlconSimbrinza$63$5,33819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 235 optometrist providers in New Hampshire.

Other optometrist in North Conway

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →